These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11694828)

  • 1. Surrogate markers for disease progression in treated HIV infection.
    Ghani AC; de Wolf F; Ferguson NM; Donnelly CA; Coutinho R; Miedema F; Goudsmit J; Anderson RM
    J Acquir Immune Defic Syndr; 2001 Nov; 28(3):226-31. PubMed ID: 11694828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001.
    Thiébaut R; Chêne G; Jacqmin-Gadda H; Morlat P; Mercié P; Dupon M; Neau D; Ramaroson H; Dabis F; Salamon R;
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):380-6. PubMed ID: 12843750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to highly active antiretroviral therapy according to duration of HIV infection.
    Pezzotti P; Pappagallo M; Phillips AN; Boros S; Valdarchi C; Sinicco A; Zaccarelli M; Rezza G;
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):473-9. PubMed ID: 11391168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men.
    Sabin CA; Devereux H; Phillips AN; Janossy G; Loveday C; Lee CA
    AIDS; 1998 Jul; 12(11):1347-52. PubMed ID: 9708415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
    Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
    HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C and progression of HIV disease.
    Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
    JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
    Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy.
    Chitra P; Bakthavatsalam B; Palvannan T
    Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.